GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) (NCT04590547), a randomized phase 2 study. The primary outcome is Number of Serious Adverse Events Relative to Treatment Group.

2. Clinical Question

The primary question is a safety question expressed as a count of participants with an event, rather than a measure of how long an event lasted or how severe it was. The posted comparisons contrast each GLS-1027 dose group with placebo. They do not, by themselves, answer every question about efficacy, dose response, or the full safety profile. The record lists additional outcomes, including hospitalization and respiratory support, but numerical results are posted for only some of them. Details of eligibility, participant characteristics, and the precise operational definition of a serious adverse event are not reported in the registry record.

3. Trial Design

The registry record describes a phase 2, randomized, triple-masked, parallel-group trial sponsored by GeneOne Life Science, Inc. Its title concerns GLS-1027 for prevention of severe pneumonitis caused by SARS-CoV-2 infection. The record lists pneumonitis and SARS-CoV infection as conditions. Enrollment was 132. The study started on 2021-05-07, reached primary completion on 2022-08-14, and is marked completed.

Three groups are described: GLS-1027 120 mg, GLS-1027 360 mg, and placebo. The 120 mg group received one 120 mg pill of GLS-1027 and two placebo pills; the 360 mg group received three 120 mg pills of GLS-1027; and the placebo group received three placebo pills. Each regimen was given by mouth once daily. The posted group sizes are 42, 46, and 44 participants, respectively.

Randomization indicates assignment by chance, while parallel-group indicates that participants were assigned to a group rather than described as crossing between treatments. Triple masking is the registry’s stated masking designation; which people or roles were masked is not reported in the registry record. The allocation method, sequence generation, concealment procedures, and handling of treatment adherence are also not reported.

The primary outcome is the number of participants with serious adverse events over 28 days. Listed secondary outcomes concern hospitalization, intensive care, non-invasive ventilation or oxygen support or mechanical ventilation, and positive end-expiratory pressure for participants who were intubated. The registry lists seven outcome measures, but numerical results are not posted for every listed measure. The protocol’s sample-size justification and detailed statistical analysis plan are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Serious Adverse Events Relative to Treatment Group, measured over 28 days.

The primary endpoint counts participants with serious adverse events relative to treatment group over 28 days. It is a binary participant-level outcome: each participant either contributes to the count by having an event or does not. The registry reports the result as a number of participants, not as a total number of separate event episodes. The record does not give a fuller endpoint definition, including the criteria used to classify an event as serious.

A serious adverse event outcome is used to describe important safety events during a defined observation period. Comparing groups can show how the observed participant counts differ, while the confidence interval expresses uncertainty around the estimated group contrast. The endpoint does not describe all possible harms, the severity or duration of every event, or whether an event was judged related to treatment. Those details are not reported in the registry record.

For the 120 mg group, 1 of 42 participants had a serious adverse event; for the 360 mg group, 3 of 46 did; and for placebo, 0 of 44 did. These counts are the posted data for the primary outcome. The endpoint is distinct from the trial’s broader stated aim of preventing severe pneumonitis: a serious adverse event count alone does not establish whether the treatment prevents pneumonitis or changes its course.

7. Results Posted in the Registry

• GLS-1027 120 mg: 2.4% (1/42) versus 0.0% (0/44) on control; risk difference 2.4 percentage points (95% CI -2.2 to 7.0); unadjusted two-proportion z-test p = 0.303.
• GLS-1027 360 mg: 6.5% (3/46) versus 0.0% (0/44) on control; risk difference 6.5 percentage points (95% CI -0.6 to 13.7); unadjusted two-proportion z-test p = 0.085.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Assess the Number of Days of Hospitalization Relative to Treatment Group

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • GLS-1027 120 mg: mean 9.30 versus 9.40 on control; difference -0.10 (95% CI -1.86 to 1.66), standardized effect d = -0.02; z-test p = 0.911.
  • GLS-1027 360 mg: mean 9.30 versus 9.40 on control; difference -0.10 (95% CI -1.71 to 1.51), standardized effect d = -0.03; z-test p = 0.903.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between GLS-1027 120 mg and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between GLS-1027 360 mg and the control. The interval gives the range of effects that remain compatible with the data.

Assess the Number of Days of NIV, High-flow O2, or Mechanical Ventilation Relative to Treatment Group

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • GLS-1027 120 mg: mean 6.70 versus 6.10 on control; difference 0.60 (95% CI -1.29 to 2.49), standardized effect d = 0.13; z-test p = 0.534.
  • GLS-1027 360 mg: mean 7.40 versus 6.10 on control; difference 1.30 (95% CI -0.45 to 3.05), standardized effect d = 0.31; z-test p = 0.145.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between GLS-1027 120 mg and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between GLS-1027 360 mg and the control. The interval gives the range of effects that remain compatible with the data.

The numerical secondary results address two related aspects of care over 28 days: hospitalization duration and the time requiring NIV, high-flow O2, or mechanical ventilation. Their overall pattern is not a consistent, precise separation between the treatment groups and placebo. The hospitalization group means are descriptively close. For respiratory-support days, the group means are not identical, but the recalculated intervals include zero and the unadjusted comparisons do not provide a precise estimate of the difference.

These outcomes complement the primary safety endpoint but do not answer the same question. Serious adverse events count participants with an event; duration outcomes summarize days in hospital or requiring respiratory support. Neither type of outcome alone establishes whether severe pneumonitis was prevented. The registry does not post numerical results for every listed secondary outcome, including ICU days and the measures concerning PEEP. Those results are not reported in the registry record.

Unadjusted secondary findings carry less weight than a prespecified primary analysis because multiple outcomes and comparisons can increase the chance of an apparently notable result arising by chance. The registry record does not report a multiplicity adjustment, an outcome hierarchy, or formal analysis results. The secondary comparisons are recalculated from summary statistics and should therefore be treated as descriptive, not as independent confirmation of a treatment effect.

The posted pattern is best read as limited evidence about the measured outcomes in these trial groups, with uncertainty remaining around the size and direction of group differences. No extrapolation to unreported outcomes, other populations, or periods beyond the stated timeframe is warranted from these summaries alone.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Assess the Number of Days of Hospitalization Relative to Treatment Group
• Assess the Number of Days Requiring ICU Care Relative to Treatment Group
• Assess the Number of Days of NIV, High-flow O2, or Mechanical Ventilation Relative to Treatment Group
• Assess the Maximal Level of Positive End-Expiratory Pressure (PEEP) for Subjects Who Are Intubated Relative to Treatment Group.
• Assess the Number of Days of PEEP > 5 cm H2O for Subjects Who Are Intubated Relative to Treatment Group

9. Statistical Interpretation

10. Statistical Methods Explained

The registry presents participant counts for the primary outcome and mean values with standard deviations for two secondary outcomes. The comparisons are recalculated, unadjusted comparisons from the posted summary statistics; no formal analysis results are listed in the registry record. General statistical explanations are identified as such.

What does a risk difference describe?

For a binary outcome, a risk difference contrasts the proportion of participants with an event in one group against the proportion in a reference group. A positive value means the observed proportion is higher in the first group; a negative value means it is lower. Here the comparator is placebo, and the event is having a serious adverse event during the 28-day timeframe. The result is a difference in proportions, not a relative risk and not a count of excess events in a future population.

The posted risk-difference estimates are recalculated from the group counts. Since the observed event counts are small and the placebo count is zero, the point estimates should not be treated as precise estimates of underlying risk. General statistical principle: when events are uncommon, a change of one or a few participants can materially affect a group’s estimated proportion. The confidence interval helps communicate the uncertainty associated with the estimate.

How should the p-values be read?

The p-values associated with the primary comparisons are unadjusted. General statistical principle: a p-value evaluates compatibility between the observed data and a specified null model under the assumptions of the test. It is not a measure of clinical importance, does not give the probability that a treatment works, and does not prove equivalence when it is not small. The registry does not report the test procedure used for a sponsor analysis, and no reported analysis results are listed.

The listed secondary comparisons are also unadjusted recalculations. Several outcomes and group comparisons create multiple opportunities for apparently notable results to occur by chance. Without a reported multiplicity strategy, individual secondary p-values should be treated as descriptive rather than confirmatory. The record does not report a prespecified hierarchy among secondary outcomes or an adjustment method.

What do the secondary mean differences represent?

Hospitalization duration and days requiring NIV, high-flow O2, or mechanical ventilation are reported as means and standard deviations. The mean difference contrasts the treatment-group mean with the placebo mean. A positive estimate indicates a higher observed mean in the treatment group; a negative estimate indicates a lower one. These outcomes are measured in days over 28 days. The recalculated comparisons use the posted group summaries, and the reported intervals describe uncertainty around the estimated differences.

A standard deviation describes variation among individual observations within a group; it is not the uncertainty of the group mean. General statistical principle: the standard error describes the sampling uncertainty of an estimate, while the standard deviation describes spread among observations. The registry posts standard deviations for these outcomes. It does not report the distribution of observations, any adjustment for baseline characteristics, or methods for dealing with skewness or unusual values.

What do the planning illustrations mean?

The sample-size illustrations are planning calculations based on observed effects, not the trial’s own design justification. They use a two-sided significance level of 0.05, equal allocation between two groups, and a normal approximation. For each outcome comparison, the illustrations consider detecting the observed effect and fractions of that effect, including planning for 75% of the observed effect. For hospitalization duration, the illustrations include 27,024 participants per arm for 80% power using 100% of the observed effect in the 120 mg comparison, and 48,043 participants per arm for 80% power using 75% of that observed effect. These are hypothetical planning quantities, not observed enrollment targets, and not evidence of the power achieved in this trial.

General statistical principle: planning estimates depend on assumptions about the effect worth detecting, variability, significance level, allocation, and analysis. When the observed effect is small, a calculation based on that estimate can produce very large planning numbers; the estimate itself is uncertain, especially in a small study. These illustrations should not be mistaken for the protocol’s sample-size calculation, which is not reported in the registry record.

The record does not report interim analyses, the handling of missing observations, a detailed analysis population, covariate adjustment, or sensitivity analyses. It is therefore not possible to assess those methodological choices from the registry record. No discrepancy is flagged between the posted counts and the recalculated summaries.

11. Confidence Intervals and Precision

Confidence intervals describe the range of estimates compatible with the data under the assumptions of the calculation. They are useful because a point estimate alone can appear more definite than the data warrant. In general, a wider interval indicates less precision. A confidence interval is not a guarantee that the true value lies within its limits, nor does it show the probability that a particular value is true.

For each primary risk-difference comparison, the posted confidence interval includes zero. Zero represents no difference in the estimated proportions between a GLS-1027 group and placebo. Since the intervals also extend to values on both sides of zero, the primary comparisons do not precisely distinguish a possible increase, no difference, or a possible decrease in the underlying event proportion. This uncertainty is consistent with the small number of observed events.

The unadjusted p-values, 0.303 for the 120 mg comparison and 0.085 for the 360 mg comparison, do not remove that uncertainty. A p-value and confidence interval are related summaries, but neither should be interpreted as proof of no effect or proof of an effect. In particular, zero observed serious adverse events in the placebo group does not mean that the true risk is precisely zero.

The secondary confidence intervals for the mean differences in hospitalization and respiratory-support days include zero as well. Their ranges indicate uncertainty in the direction and size of the group contrasts. The group means and standard deviations provide useful descriptive context, but they cannot substitute for individual-level data or reveal whether the outcome distributions were skewed. General statistical principle: precision depends on both the amount of information and the variability in the observations; a small p-value is not itself a measure of precision.

The registry does not report confidence intervals for every listed outcome, and detailed methods for interval construction are not reported in the registry record. The recalculated intervals should therefore be read as unadjusted summaries from posted data, rather than as a complete account of uncertainty across all outcomes.

12. Multiplicity, Missing Data and Analysis Populations

The registry record lists a primary outcome and several secondary outcomes, with comparisons of two GLS-1027 dose groups against placebo. When many outcomes or comparisons are examined, the chance of seeing at least one apparently notable result by chance can increase. General statistical principle: multiplicity procedures, such as a prespecified testing order or an adjustment to the significance threshold, can address this issue, but the appropriate strategy depends on the study’s aims and analysis plan.

A multiplicity strategy is not reported in the registry record. The posted comparison p-values are unadjusted recalculations, and the record does not give a hierarchy specifying which secondary outcomes should be treated as confirmatory. Consequently, the secondary p-values should not be read as if they came from a single isolated test. The registry also does not provide formal analysis results for the primary outcome.

Missing-data handling is not reported in the registry record. The record does not state whether all randomized participants were included in each outcome analysis, whether any observations were missing, how missing observations were handled, or whether sensitivity analyses were conducted. The displayed group sizes and outcome counts do not establish the analysis population or show whether every randomized participant contributed data to every endpoint.

The analysis population is also not reported in the registry record. It is not possible from the posted summaries to determine whether the comparisons followed an intention-to-treat approach, a per-protocol approach, or another defined population. Details such as protocol deviations, treatment discontinuation, and follow-up completeness are likewise not reported.

These omissions matter because analysis choices can affect estimates and uncertainty. They do not demonstrate that the analyses were inappropriate; they mean that these features cannot be evaluated from the registry record. A full protocol or clinical study report could contain additional detail, but such information is not reported in the registry record.

13. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 3% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: cardiopulmonary failure (2.4%), cerebrovascular accident (2.2%), ischaemic stroke (2.2%), respiratory failure (2.2%).

For serious adverse events, the posted counts are 1 participant in the GLS-1027 120 mg group, 3 in the GLS-1027 360 mg group, and 0 in the placebo group. The corresponding groups included 42, 46, and 44 participants. These are counts of participants with an event, not counts of all event episodes. The zero in the placebo group is an observed count and should not be interpreted as evidence that no such events can occur.

The registry also reports other adverse events affecting 2 participants in the 120 mg group, 3 in the 360 mg group, and 1 in the placebo group, as well as deaths of 1, 1, and 0 participants, respectively. The record does not report whether deaths or other events were considered related to treatment, nor does it describe timing, severity beyond the serious-event classification, or follow-up after the 28-day primary timeframe.

The listed top serious-event terms include cardiopulmonary failure at 2.4%, cerebrovascular accident at 2.2%, ischaemic stroke at 2.2%, and respiratory failure at 2.2%. Group attribution and the precise denominator for these term percentages are not reported in the registry record. These figures should not be combined or interpreted as group-specific risks without that context. The small counts and incomplete detail limit what can be concluded about comparative safety.

14. What the Result Does, and Does Not, Mean

The primary result describes the observed number of participants with serious adverse events during 28 days in each randomized group. It shows that the counts were 1, 3, and 0 across the 120 mg, 360 mg, and placebo groups. The recalculated unadjusted risk-difference intervals include zero, leaving considerable uncertainty about the underlying group differences. The data therefore do not precisely establish either an increase or a decrease in serious adverse event risk.

That interpretation is specific to the endpoint, timeframe, and participants represented by the registry results. It does not establish whether GLS-1027 prevents severe pneumonitis, whether any dose has a particular efficacy, or whether the treatment has a particular overall safety profile. The posted primary endpoint is serious adverse events, not a direct numerical measure of prevention efficacy. The registry lists secondary outcomes relevant to hospitalization and respiratory support, but only some have numerical results.

A lack of a clearly separated comparison is not proof that the groups are equivalent. Equivalence or non-inferiority requires a prespecified margin and an appropriate design and analysis; those are not reported in the registry record. Conversely, a difference in observed counts does not establish causation or clinical importance. The p-values are unadjusted and should not be treated as probabilities that an observed pattern is due to chance or that a treatment effect is true.

The trial is marked completed, but the record does not report details needed to assess eligibility, participant characteristics, missing data, analysis populations, or adherence. The findings should be understood as registry-level summaries from this phase 2 trial, not as a complete description of the trial’s methods or a basis for conclusions beyond the posted data.

15. Why This Trial Matters Statistically

This trial illustrates why event counts, point estimates, and uncertainty need to be read together. The primary outcome has few observed events, including no events in the placebo group. A group count alone can look decisive, but the recalculated confidence intervals show that the comparative estimates remain compatible with a range of possibilities. Small event counts make a precise estimate difficult.

It also demonstrates the importance of matching interpretation to the endpoint. The stated trial purpose concerns prevention of severe pneumonitis, while the posted primary outcome measures serious adverse events. Secondary measures concern hospitalization and respiratory support. Each contributes a different kind of information, and none should be treated as a substitute for the others. A safety endpoint does not directly quantify prevention efficacy.

The registry’s secondary comparisons and planning illustrations provide a further statistical lesson. Unadjusted secondary p-values do not account for examining multiple outcomes, and planning calculations based on observed effects are not the trial’s design justification or observed power. The record does not report a sample-size rationale, multiplicity plan, or detailed analysis plan, so those design decisions cannot be assessed from the registry results.

For biostatisticians and clinical researchers, the case underscores the value of reporting outcome definitions, analysis populations, missing-data handling, and methods alongside numerical results. Without these details, readers can describe the posted summaries and their precision, but cannot fully evaluate how the analyses were specified or whether all relevant outcomes were measured and reported.

16. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record does not provide detailed eligibility criteria or participant characteristics, limiting assessment of who the findings represent. It also does not describe how randomization was generated or concealed, which roles were masked, or how adherence and treatment discontinuation were handled. These are reporting gaps; they do not, by themselves, show that the procedures were inadequate.

The primary outcome is reported as a participant count, but a detailed definition of serious adverse events and rules for event attribution are not reported. Event timing and whether events were judged related to treatment are also not reported. The posted event counts are small, and the placebo group has no observed serious adverse events, limiting the precision of group comparisons.

The registry does not report an analysis population, missing-data methods, sensitivity analyses, multiplicity plan, interim analyses, or the statistical analysis plan. Although the record lists several secondary outcomes, numerical results are not reported for all of them. The two posted secondary outcomes do not provide a complete view of hospitalization, intensive care, respiratory support, or PEEP outcomes listed in the record.

The recalculated comparisons use posted summary statistics and are unadjusted. They cannot account for unreported baseline characteristics, participant-level outcome distributions, or analysis choices. The sample-size illustrations are based on observed effects and are not the trial’s own design calculations. These limitations mean the registry summaries support a cautious description of the recorded results, not a comprehensive assessment of the trial’s conduct or all its findings.

17. Related Tutorials

18. Related Statistical Calculators

19. Sources

• ClinicalTrials.gov: GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) — NCT04590547.
• Registry record last updated 2025-04-11; status last verified 2025-03.
• Results first posted 2025-04-11.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

20. Record Summary

NCT04590547 is a completed phase 2, randomized, triple-masked, parallel-group trial sponsored by GeneOne Life Science, Inc. The record lists enrollment of 132, a start date of 2021-05-07, and primary completion on 2022-08-14. Participants were assigned to GLS-1027 120 mg, GLS-1027 360 mg, or placebo, taken orally once daily.

The primary outcome was the number of participants with serious adverse events over 28 days. The posted counts were 1 of 42, 3 of 46, and 0 of 44 for the 120 mg, 360 mg, and placebo groups, respectively. Recalculated unadjusted comparisons have confidence intervals that include zero. Numerical secondary results are posted for hospitalization duration and days requiring NIV, high-flow O2, or mechanical ventilation; results for other listed secondary outcomes are not reported in the registry record.

Detailed analysis populations, missing-data procedures, multiplicity methods, and the protocol’s sample-size justification are not reported in the registry record. The posted summaries therefore permit description of the observed counts and estimates, but leave important aspects of analysis and interpretation uncertain.